What is Leerink Partnrs’ Estimate for GPCR Q1 Earnings?

Structure Therapeutics Inc. (NASDAQ:GPCR) – Equities researchers at Leerink Partnrs issued their Q1 2025 EPS estimates for Structure Therapeutics in a research report issued to clients and investors on Monday, March 3rd. Leerink Partnrs analyst D. Risinger anticipates that the company will post earnings per share of ($0.24) for the quarter. The consensus estimate for Structure Therapeutics’ current full-year earnings is ($0.82) per share. Leerink Partnrs also issued estimates for Structure Therapeutics’ Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.29) EPS, FY2025 earnings at $1.80 EPS and FY2029 earnings at $1.03 EPS.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01.

A number of other equities research analysts also recently weighed in on the stock. William Blair began coverage on shares of Structure Therapeutics in a research note on Friday. They issued an “outperform” rating on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 target price on shares of Structure Therapeutics in a research note on Thursday, December 19th. JMP Securities reissued a “market outperform” rating and set a $91.00 price target on shares of Structure Therapeutics in a research note on Wednesday, December 18th. Finally, Stifel Nicolaus assumed coverage on shares of Structure Therapeutics in a research note on Wednesday, January 8th. They set a “buy” rating and a $50.00 price target on the stock. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $81.29.

Structure Therapeutics Price Performance

Shares of GPCR opened at $22.34 on Tuesday. The firm’s 50 day simple moving average is $26.45 and its 200 day simple moving average is $33.47. The company has a market capitalization of $1.28 billion, a P/E ratio of -30.19 and a beta of -2.75. Structure Therapeutics has a 1-year low of $19.61 and a 1-year high of $62.74.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in GPCR. ANTIPODES PARTNERS Ltd increased its stake in shares of Structure Therapeutics by 115.0% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company’s stock worth $28,000 after buying an additional 553 shares during the period. GAMMA Investing LLC increased its stake in shares of Structure Therapeutics by 4,155.6% in the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock worth $31,000 after buying an additional 1,122 shares during the period. GF Fund Management CO. LTD. purchased a new position in shares of Structure Therapeutics in the fourth quarter worth $34,000. FNY Investment Advisers LLC purchased a new position in shares of Structure Therapeutics in the fourth quarter worth $40,000. Finally, Assetmark Inc. increased its stake in shares of Structure Therapeutics by 120.0% in the third quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock worth $58,000 after buying an additional 719 shares during the period. 91.78% of the stock is owned by hedge funds and other institutional investors.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.